key: cord-0710501-qgtvpvfh
authors: Qian, Wenwei; Ye, Ying; Zuo, Lugen; Song, Ting; Xu, Qing; Wang, Yinghong; Qian, Jun; Tian, Yun
title: Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis
date: 2021-08-25
journal: Immunotherapy
DOI: 10.2217/imt-2021-0007
sha: fbdcc618b7bf1c0f54033123320132c5b4f0589b
doc_id: 710501
cord_uid: qgtvpvfh

Aim: We aimed to quantify the effects of immune checkpoint inhibitors (ICIs) on the prognosis of COVID-19. Materials & methods: A meta-analysis was conducted and the hospitalization, severe disease and mortality rates were assessed. Thirteen studies comprising of 4614 cancer patients with COVID-19 were included. Results: When compared with cancer patients without prior ICI exposure, patients with prior ICI treatment exhibited a higher rate of hospitalization (odds ratio [OR] 2.0, 95% CI 1.19–3.38, p = 0.01). However, the OR of severe disease and mortality in ICI exposed cases was similar to non-ICI exposed patients (OR 1.55, 95% CI 0.69–3.51, p = 0.29; OR 1.12, 95% CI 0.85–1.48, p = 0.42, respectively). Conclusion: It is uncertain whether prior exposure to ICIs increases the risk of severe disease and death, however the observed OR suggest a higher rate of hospitalization.

. Main characteristics of the included studies in meta-analysis. Three excluded as they were surveys 21 excluded as the number of included patients was fewer than 4 outcome assessment and produces scores ranging from 0 to 9. Studies with NOS scores of >7 were regarded as high quality. The risk of bias was independently assessed by two authors (W Qian and Y Tian).

All statistical analyses in this study were performed using R (version 4.0.2). Odds ratios (OR) were used to describe the ratio of the probability of events occurring in cancer patients treated with different therapies. The q-test was used to calculate heterogeneity among the included studies and I 2 test was used to describe the percentage of variation across studies that is due to heterogeneity. p < 0.05 or I 2 > 50% indicated substantial heterogeneity across the articles [16] , and a random effects model was used [17] . Otherwise, a fixed-effects model was used. Publication bias was assessed using the Begg funnel plot and the Egger test linear regression test (where at least five studies were available). A p < 0.05 was considered statistically significant.

The search strategy identified 1508 articles ( Figure 1 ). Among these studies, 375 were duplicates. After screening the title and abstract, 1085 were excluded, and the full text of the remaining 38 articles was reviewed. Among these, one study about coronavirus, three surveys and 21 researches that included less than four patients were excluded after full text review. Finally, 13 studies reported ICI use in cancer patients and prognosis of COVID-19 infection [8, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . The 13 articles consisted of ten cohort studies and three case series and were included for the meta-analysis.

Finally, 13 relevant studies were enrolled, including eight retrospective studies and five prospective studies, comprising more than 4600 cancer patients infected by COVID-19. Detailed patient characteristics of the included studies are shown in Table 1 . The studies were from eight countries, including China (n = 2), Germany (n = 2), Italy (n = 2), France (n = 2), Spain (n = 2), the UK (n = 3) and the USA (n = 3). These studies included more than four ICI users, and the median age of study participants was 61-67 years old. Of these 13 studies, clinical outcomes were defined as hospitalization in five studies, severity in eight studies and mortality in 11 studies (Table 1) . However, there was nonuniformity in the criterion of the time interval from last dose to COVID-19 diagnosis (Table 1) [8, 18, 19, 21, [23] [24] [25] .

Results of the quality assessment of the included studies assessed by NOS scores are presented in Table 1 .

We combined five studies [20, 23, 25, 27, 28] reporting the hospitalization of COVID-19 infection in patients on ICI treatment, and a random effects model was used since the heterogeneity test suggested obvious heterogeneity (I 2 = 87%, p < 0.01). The pooled estimate of the rate of hospitalization was 0.45 (95% CI 0.15-0.78; Table 2 ). Four of the five studies [20, 23, 25, 27] contained hospitalization information of patients without ICI exposure. The proportion of hospitalization was markedly increased in patients treated with ICI therapy compared with those without ICI treatment (OR 2.00 [95% CI 1.19-3.38], p = 0.01; I 2 = 45%; Figure 2A ).

Eight studies [8, 18, 20, 23, 24, [27] [28] [29] that included 111 COVID-19 cases with ICI exposure reported on COVID-19 severity in relation to ICI exposure. The combined proportion of severe disease was 0.34 (95% CI 0.26-0.44, I 2 = 35%; Table 2 ). Out of these eight studies, five studies [8, 18, 20, 23, 27] included 83 COVID-19 cases with ICI exposure and 809 COVID-19 cases unexposed to ICI. A random-effects model was used (I 2 = 55%; p = 0.06) and the pooled OR of COVID-19 severity was 1.55 (95% CI, 0.69-3.51, p = 0.29; Figure 2B ).

The overall analysis included 11 studies [8, [18] [19] [20] [21] [22] [23] [24] 26, 28, 29] . Together, 299 COVID-19 cases with ICI exposure and 3188 COVID-19 cases without ICI exposure were included. The pooled proportion of mortality in COVID-19 patients with ICI exposure was 0.26 (95% CI, 0.17-0.38; Table 2 ). Next, the risk associated with ICI use and mortality was assessed. Overall, the OR of mortality in ICI-exposed cases was similar to non-ICI exposed COVID-19 patients (OR 1.12, 95% CI 0.85-1.48, p = 0.42; Figure 2C ). Moderate heterogeneity was observed among the studies (I 2 = 42%, p = 0.11). We further examined the mortality between exposure to ICI and other treatments in cancer patients in the context of COVID-19. However, we did not identify significant differences between ICI and chemotherapy (OR 1.09, 95% CI 0.81-1.48, p = 0.56; I 2 = 0%; Figure 3A ), hormone therapy (OR 1.45, 95% CI 0.70-2.97, p = 0.32; I 2 = 53%; Figure 3B ), radiotherapy (OR 1.13, 95% CI 0.74-1.74, p = 0.57; I 2 = 26%; Figure 3C ), surgery (OR 1.69, 95% CI 0.95-2.98, p = 0.57; I 2 = 0%; Figure 3D ), except for targeted therapy (OR 2.13, 95% CI 1.44-3.14, p < 0.01; I 2 = 15%; Figure 3E ).

Given that the receptor can be occupied for months [30] and the initial start of ICI therapy results in a distinct proliferative burst [31] [32] [33] [34] , different intervals from the last dose of ICI to the diagnosis of COVID-19 may theoretically influence the prognosis of COVID-19 infection. Luo et al. [23] defined five categories of prior PD-1 blockade, including no prior PD-1, ever received PD-1 blockade, last receipt within 6 months, last receipt within 6 weeks, and first receipt within 3 months, detecting the outcomes of interest. Overall, there was no significant difference in prognosis regardless of PD-1 blockade exposure. We extracted data from this study and regrouped patients according to intervals from last dose of ICI to the diagnosis of COVID-19: no prior PD-1, interval >6 months, interval between 6 months and 6 weeks, interval <6 weeks and initial dose within 3 months ( Figure 4 ). However, we did not capture any statistically significant differences between no prior PD-1 group and the other four groups tested by chi-square test or Fisher's exact test in terms of prognosis, including hospitalization, severe disease and mortality ( Figure 4) . Consistent with the above outcomes, Wu et al. [29] observed a similar risk of severity in different intervals from the last ICI administration to COVID-19 diagnosis (interval ≥28 days vs interval <28 days, p = 1.00). Week. Data taken from [23] .

ICI-induced pneumonitis presents similar clinical and radiological features to COVID-19, challenging the early diagnosis of COVID-19 [35] . Guerini et al. [36] and Lovly et al. [37] reported two cases where patients experienced misdiagnosis caused by ICI-induced pneumonitis and later died due to an uncontrolled COVID-19 infection. Clinicians should always consider COVID-19 as a differential diagnosis, as few places were spared during the pandemic. In another report [38] , two patients were initially highly suspected of COVID-19 infection based on clinical manifestations, imaging findings and epidemiology. Steroids were withheld in one case, and the disease became worse until a third CT scan was obtained, and a second negative RT-PCR test was released after admission. Both patients were eventually diagnosed with ICI-induced pneumonitis, and a mean delay of 3 days in steroid initiation was attributed to the COVID-19 pandemic. Except for missed window of optimal treatment caused by delayed diagnosis, ICI-induced pneumonitis itself reduces patient resistance and exacerbates COVID-19 infection. Here, we were curious about the influence of ICI in lung cancer patients infected with COVID-19. Data showed that ICI application did not significantly influence the severity of COVID-19 in lung cancer patients (ICI application [7/12] vs no ICI application [8/23] , p = 0.181) [27] . Consistently, ICI exposure in lung cancer patients did not exhibit a higher risk for developing severity than in patients with other solid cancers (lung cancer [7/12] vs other solid cancers [5/19] , p = 0.13) [27] .

The results of publication bias was shown in Table 2 , which was assessed using the Begg's funnel plot and Egger's test. There was no significant publication bias in the included studies (all p > 0.5).

This review included 13 articles that encompassed 409 ICI users infected with COVID-19. It is uncertain whether prior exposure to ICI increases the risk of severe disease and death but, observed OR suggests a higher rate of hospitalization. In addition, different intervals from the last dose of ICI to diagnosis of COVID-19 might not influence the prognosis of COVID-19 infection. Finally, given the unpredictable duration of the pandemic, we should always keep in mind a differential diagnosis of COVID-19 and rational adjustment of ICI use.

Patients with cancer are theoretically more vulnerable to infection due to poor health status and immunosuppressive conditions provoked by both the cancer and antitumor therapies [39] [40] [41] [42] . Poorer prognosis in COVID-19 infection has been associated with several factors, including older age, gender and comorbidities such as pulmonary disease, cardiac disease, hypertension and cancer [26, 43] . Liang et al. collected and analyzed 1590 cases from 575 hospitals [7] . In their study, 18 of 1590 (1%; 95% CI 0.61-1.65) COVID-19 cases had a history of cancer, which was higher than the overall incidence of cancer in the population (285.83 [0.29%] per 100,000 people). Importantly, patients with cancer exhibited a higher rate of severe disease than patients without cancer (7/18 [39%] vs 124/1572 [8%], p = 0.0003). Here, we pooled the prognostic data from COVID-19-infected cases with prior exposure to ICI. The rate of hospitalization was 45%, 34% developed severe disease and 26% died.

Physicians worry about the influence of ICI administration on COVID-19 infection for two main reasons [44] . The first is the potential overlap between the two lung injuries: possible pneumological toxicity from ICI use and COVID-19 pneumonia. The incidence of ICI-related pneumonitis was reported to be 2.5-5% with anti-PD-1/PD-L1 monotherapy and 7-10% with anti-CTLA-4/anti-PD-1 combination therapy [45] . These fatal immune-related adverse events accounted for 35% of treatment-related deaths [46] . The second concern is the potential synergy between ICI mechanisms and COVID-19 pathogenesis, both of which are involved in immune hyperactivation [47] [48] [49] . Integrating multiple studies into the present study, we found that prior receipt of ICI significantly increased the rate of hospitalization. In contrast, there was no significant difference in severe disease and mortality among patients with or without prior ICI exposure (OR 1.55, 95% CI 0.69-3.51, p = 0.29; OR 1.12, 95% CI 0.85-1.48, p = 0.42; Figure 2B & C). We speculate that prior ICI exposure may lead to gastrointestinal and respiratory symptoms in some patients, which could contribute to more hospitalization.

Most of the included studies focused on the impact of ICI use or not on the prognosis of COVID-19 [8, [18] [19] [20] [21] [22] ], but they did not take other important factors into consideration, including courses of ICI use, intervals from the last dose to the diagnosis of COVID-19, and the effect of the first dose. Wu et al. [29] found that patients who received three or more cycles of ICI were more likely to develop severe COVID-19, albeit this difference was not statistically significant (6/7 [85.7%] vs 1/4 [25%], p = 0.09). Another study [23] included 69 patients and defined five groups according to the interval from last ICI receipt to COVID-19 diagnosis. Overall, there was no statistically significant difference in different groups in terms of the rate of hospitalization, severe disease or death.

As the influence of ICI on cancer patients infected with COVID-19 is not clear, there are no authoritative guidelines for ICI modifications in the context of COVID-19. Modifications of drug application are often empirical and based on the mechanism of drug action, taking tumor treatment and epidemic prevention into account [50] . Wang [51] et al. suggested that administration of anticancer drugs should be changed from infusion to oral administration if available. For maintenance therapy, we could appropriately prolong the infusion intervals according to patient condition. Aeppli et al. performed an online survey among physicians involved in the treatment of renal cell carcinoma [14] . Compared with that outside the pandemic, the use of ipilimumab/nivolumab fell by half in intermediate/poor-risk patients during the pandemic (80 vs 41%). In patients responding to established ICIcontaining therapies, most participants modified treatment regimen by extending cycle length. Another survey focused on patient perspective on oncological care [52] . In patients with adjusted treatment, immunotherapy (32%) was most frequently adjusted. Consistently, in patients with delay and discontinuation of treatment (39 and 33%, respectively), immunotherapy was the most frequently included modality.

This study has important implications for clinical practice. Given that the pandemic may last for another several months or even years, physicians should balance cancer treatment and COVID-19 infection. Our results indicate that ICI administration increases the rate of hospitalization, though it is uncertain whether prior exposure to ICI increases the risk of severe disease and death. This suggests that we should not easily postpone, suspend or alter our established treatment decisions in clinical practice, especially for patients who are undergoing ICI-containing regimens, because ICI has irreplaceable performance in certain antitumor treatments [12] . Delay or modification of therapy should be considered on a case-by-case basis [53] .

This systematic review and meta-analysis has several limitations. The most important limitation is that we could not rule out unknown confounders. Previous studies reported that age, sex, smoking and comorbidities, including pulmonary disease, cardiac disease, and hypertension, significantly affect the prognosis of COVID-19 infection. However, these potential confounders were not considered in most of the included studies. What is more, in the absence of a head-to-head comparison between ICIs, the choice to perform an evaluation as a new pharmacological class is theoretically unsound. However, among all the researches enrolled in the binary outcome, we found that none of the studies could provide prognosis information about the different ICI molecules. Second, due to the relatively small number of studies, we were unable to evaluate the effects of ICI subclasses or line of treatment or their role in individual tumors. Low proportion of patients treated with immunotherapy would unavoidably confound the meta-analysis results to some extent. Additionally, the benefit of longer duration of ICI on the overall survival has been determined, and frequent or early interruption of ICI has been proved to be associated with worse overall survival [12] . It will be worthwhile to comment on the cancer outcome in this population. However, limited by a short follow-up period, we failed to assess the cancer outcome in patients who had delayed or interrupted ICI treatment through published studies. Further, studies on the association between immune-related adverse events and COVID-19 risk, and outcome are needed. At last, included studies defined several intervals from the last dose to the diagnosis of COVID-19 infection, which may have influenced the findings.

The results of this meta-analysis suggest that a higher rate of hospitalization was observed among patients who were undergoing ICI-containing regimens, although it is uncertain whether prior exposure to ICI increases the risk of severe disease and death. Additionally, different intervals from last dose of ICI to the diagnosis of COVID-19 may not influence the prognosis of COVID-19 infection.

• The influence of prior exposure to immune checkpoint inhibitors (ICIs) on COVID-19 infection remains largely unknown. • It is necessary to perform a meta-analysis to quantify the effects of ICI on the prognosis of COVID-19.

• We systematically searched the PubMed, Embase and Web of Science databases.

• We included studies that reported ICI use in cancer patients and their prognosis in the context of COVID-19.

• Chi-squared and I 2 tests were used to calculate heterogeneity among the included studies, and the choice of random or fixed effects model was made according to the heterogeneity. • Thirteen studies comprising 4614 cancer patients with COVID-19 were included for the systematic review and meta-analysis. • The pooled rate of hospitalization, severe disease, and mortality in patients with prior exposure to ICI was 0.45 (95% CI 0.15-0.78), 0.34 (95% CI 0.26-0.44) and 0.26 (95% CI 0.17-0.38), respectively. • When compared with cancer patients without prior ICI exposure, patients with prior ICI treatment exhibited a higher rate of hospitalization (odds ratio 2.0, 95% CI 1.19-3.38, p = 0.01). • No statistically significant difference in mortality was observed between patients exposed to ICI and other antitumor treatments in the context of COVID-19, except for the targeted therapy. • It is uncertain whether prior exposure to ICI increases the risk of severe disease and death but observed odds ratio suggest a higher rate of hospitalization.

Author contributions Y Tian, W Qian and J Qian contributed to conception and design. Y Tian, W Qian, Y Ye, L Zuo and T Song contributed to acquisition of data. W Qian, Y Ye, L Zuo and Y Tian contributed to analysis and interpretation of data. W Qian, Y Tian, L Zuo, J Qian and Y Wang contributed to writing, review and revision of the manuscript. All authors contributed to final approval of manuscript.

This study was supported by Natural Science Foundation of Shanghai (grant 19ZR1447100) and Foundation of Shanghai Dermatology Hospital (grants 17HBDS08 and 2018KYQD02). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72-314 cases from the Chinese Center for Disease Control and Prevention

SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis

Update: public health response to the coronavirus disease 2019 outbreak -United States

Symptom clusters in COVID-19: a potential clinical prediction tool from the COVID Symptom Study app

Extrapulmonary manifestations of COVID-19

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak

Case fatality rate of cancer patients with COVID-19 in a New York hospital system

Immunometabolic status of COVID-19 cancer patients

Cancer immunotherapy: harnessing the immune system to battle cancer

Immune checkpoint inhibitors: recent progress and potential biomarkers

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: warfarin versus aspirin in reduced cardiac ejection fraction trial substudy

Measuring inconsistency in meta-analyses

Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG

COVID-19 outcomes of patients with gynecologic cancer in New York City

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Risk factors for Coronavirus disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19)

Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers

on the impact of immune checkpoint inhibitor on severity of COVID-19 in patients with cancers and defines five groups according to the interval from last immune checkpoint inhibitor receipt to COVID-19 diagnosis

SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: a survey of the German ADOREG melanoma registry

Impact of SARS-CoV-2 infection on patients with cancer: retrospective and transversal studies in Spanish population

Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients

Determinants of COVID-19 disease severity in patients with cancer

Clinical characteristics and outcome for four SARS-CoV-2-infected cancer patients treated with immune checkpoint inhibitors

Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Peripheral CD8(+) T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma

Peripheral T cell expansion predicts tumour infiltration and clinical response

COVID-19 pneumonia mimicking immunotherapy-induced pneumonitis on 18F-FDG PET/CT in a patient under treatment with nivolumab

Differential diagnosis and clinical management of a case of COVID-19 in a patient with stage III lung cancer treated with radio-chemotherapy and durvalumab

Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer

Immune-related pneumonitis with nivolumab and ipilimumab during the coronavirus disease 2019 (COVID-19) pandemic

Nosocomial infections in patients with cancer

Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer

Features of postoperative immune suppression are reversible with interferon gamma and independent of interleukin-6 pathways

Myeloid suppressor cells in cancer and autoimmunity

Comorbidities and multi-organ injuries in the treatment of COVID-19

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors

Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors

Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis

Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr

Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Rethinking the optimal duration of immune checkpoint inhibitors in non-small cell lung cancer throughout the COVID-19 pandemic

Active and effective measures for the care of patients with cancer during the COVID-19 spread in China

Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective

Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo-or immunotherapy